| Not Yet Recruiting | Di-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney Disease NCT06786260 | Loma Linda University | N/A |
| Recruiting | Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease NCT07454174 | Richard Fatica | N/A |
| Recruiting | Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) NCT07161037 | Vertex Pharmaceuticals Incorporated | Phase 2 |
| Not Yet Recruiting | Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects NCT07181265 | Jemincare | Phase 1 |
| Recruiting | Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney Disease NCT07260071 | King's College London | — |
| Completed | Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants NCT07074327 | Vertex Pharmaceuticals Incorporated | Phase 1 |
| Completed | A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants NCT07022119 | Vertex Pharmaceuticals Incorporated | Phase 1 |
| Active Not Recruiting | Simulated and Synthetic Health Data: Improving Clinical Research on Rare Diseases. A Real-World Data Simulatio NCT07016282 | Mario Negri Institute for Pharmacological Research | — |
| Recruiting | Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003 NCT06714006 | PYC Therapeutics | Phase 1 |
| Completed | A Possible Founding PKD2 Mutation Associated With Variable Phenotypes of ADPKD in Bergamo Province NCT06594367 | Mario Negri Institute for Pharmacological Research | — |
| Active Not Recruiting | Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease NCT06747572 | Vertex Pharmaceuticals Incorporated | — |
| Active Not Recruiting | Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney Di NCT06688981 | Mario Negri Institute for Pharmacological Research | — |
| Completed | A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants NCT06345755 | Vertex Pharmaceuticals Incorporated | Phase 1 |
| Active Not Recruiting | Study of Tamibarotene in Patients With ADPKD NCT06289998 | Rege Nephro Co., Ltd. | Phase 2 |
| Active Not Recruiting | Robotic vs Open Nephrectomy for ADPKD NCT07355114 | University of Bologna | — |
| Completed | Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases NCT04689074 | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari | — |
| Recruiting | RADIOLOGICAL AND CLINICAL EVALUATION OF RENAL EMBOLIZATION USING EVOH IN DIALYSIS PATIENTS WITH AUTOSOMAL DOMI NCT07535385 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Completed | Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Auto NCT03949894 | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 4 |
| Completed | Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autos NCT02964273 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 |
| Completed | Canadian Medical Assessment of JINARC™ Outcomes Registry NCT02925221 | Otsuka Canada Pharmaceutical Inc. | — |
| Terminated | Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD01 NCT02616055 | Kadmon Corporation, LLC | Phase 2 |
| Completed | Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD NCT02112136 | University Hospital, Brest | N/A |
| Completed | Lanreotide In Polycystic Kidney Disease Study NCT02127437 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease NCT02225860 | Tufts Medical Center | Phase 2 / Phase 3 |
| Unknown | Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) NCT02115659 | Shanghai Changzheng Hospital | Phase 3 |
| Unknown | Study of Lanreotide to Treat Polycystic Kidney Disease NCT01616927 | University Medical Center Groningen | Phase 3 |
| Completed | Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease NCT01430494 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — |
| Completed | A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Poly NCT01280721 | Otsuka Pharmaceutical Co., Ltd. | Phase 3 |
| Terminated | Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency NCT01223755 | Mario Negri Institute for Pharmacological Research | Phase 2 / Phase 3 |
| Completed | Tolvaptan Extension Study in Participants With ADPKD NCT01214421 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 |
| Completed | Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) NCT00346918 | University of Zurich | Phase 3 |
| Completed | Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study NCT00309283 | Mario Negri Institute for Pharmacological Research | Phase 3 |